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Background: The use of nicotine replacement therapy before quitting smoking is called nicotine preloading.
Standard smoking cessation protocols suggest commencing nicotine replacement therapy only on the first day of
quitting smoking (quit day) aiming to reduce withdrawal symptoms and craving. However, other, more successful
smoking cessation pharmacotherapies are used prior to the quit day as well as after. Nicotine preloading could
improve quit rates by reducing satisfaction from smoking prior to quitting and breaking the association between
smoking and reward. A systematic literature review suggests that evidence for the effectiveness of preloading is
inconclusive and further trials are needed.
Methods/Design: This is a study protocol for a multicenter, non-blinded, randomized controlled trial based in the
United Kingdom, enrolling 1786 smokers who want to quit, funded by the National Institute for Health Research,
Health Technology Assessment program, and sponsored by the University of Oxford. Participants will primarily be
recruited through general practices and smoking cessation clinics, and randomized (1:1) either to use 21 mg nicotine
patches, or not, for four weeks before quitting, whilst smoking as normal. All participants will be referred to receive
standard smoking cessation service support.
Follow-ups will take place at one week, four weeks, six months and 12 months after quit day. The primary
outcome will be prolonged, biochemically verified six-month abstinence. Additional outcomes will include point
prevalence abstinence and abstinence of four-week and 12-month duration, side effects, costs of treatment, and
markers of potential mediators and moderators of the preloading effect.
Discussion: This large trial will add substantially to evidence on the effectiveness of nicotine preloading, but also
on its cost effectiveness and potential mediators, which have not been investigated in detail previously. A range
of recruitment strategies have been considered to try and compensate for any challenges encountered in recruiting
the large sample, and the multicentre design means that knowledge can be shared between recruitment teams. The
pragmatic study design means that results will give a realistic estimate of the success of the intervention if it were to
be rolled out as part of standard smoking cessation service practice.
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People who try to stop smoking typically experience
urges to smoke, often described as cravings, frequently
in response to environmental cues associated with smok-
ing (such as drinking alcohol). These urges decrease in
intensity and frequency with time. The key to stopping
smoking is to resist these urges. Effective medication
for smoking cessation reduces the intensity of the urges
[1,2], and this is the likely mechanism of action.
There are three licensed medications for smoking ces-
sation: bupropion, varenicline, and nicotine replacement
therapy (NRT). Varenicline is a nicotinic partial agonist and
it is therefore surprising to find that it is more effective than
a full agonist, nicotine [3]. An investigation considered the
possible mechanisms of action and compared varenicline,
bupropion, and a placebo [4]. It found that varenicline
reduced urges to smoke to a lower level than did bupro-
pion. Furthermore, varenicline led to lower satisfaction
from a lapse (smoking episode) after quit day than did
bupropion. However, many other mood-related symptoms
of withdrawal were of similar intensity. This suggests
that a key mechanism of action of the smoking cessation
pharmacotherapies, which relates directly to efficacy, is
controlling urges and reducing satisfaction from smoking.
Unlike NRT, varenicline is used for one to two weeks prior
to quit day, which might explain its superior efficacy.
Using NRT while smoking reduces satisfaction from
smoking [5] and so it seems logical to examine whether
NRT used prior to quitting could make smoking cessation
more successful. This is known as nicotine preloading.
The mechanism above is widely assumed to underlie
the apparent effectiveness of preloading. If true, it should
work independently of whether or not a person uses
pharmacotherapy after cessation, or the type of pharmaco-
therapy used. The proposed mechanism is essentially that
nicotine preloading reduces satisfaction from smoking,
and this begins to undermine the learned association
between smoking and reward.
Evidence from systematic reviews and meta-analyses
Two previously published systematic reviews of nico-
tine preloading [6,7] reported very positive results, with
Shiffman and Ferguson [7] giving an odds ratio (OR) of
1.96, 95% confidence interval (CI): 1.31 to 2.93 for six
weeks abstinence, and an OR of 2.17, 95% CI: 1.46 to
3.22 for six months. The Cochrane review [6] gave a
risk ratio (RR) of 1.79 (95% CI = 1.17, 2.72 for long-term
abstinence (six or 12 months).
In preparing the application for the reported trial, we
undertook an updated meta-analysis [8]. This meta-analysis
also investigated three hypotheses to examine the possible
mechanisms of action and explain the variation in results
observed in the existing clinical trials. We included four
more studies than previous reviews and the evidence wasbased on a meta-analysis of 2813 participants. The main
findings of this review are as given below.
Our review showed much less evidence of efficacy
than the earlier reviews. There was a weak, positive, but
non-significant effect of preloading versus placebo and/
or no treatment on short-term abstinence (RR = 1.05,
95% CI = 0.92, 1.19, P = 0.49), with marked heterogeneity
(I2 of 69%, P = 0.002). The effect on long-term abstinence
gave a slightly larger but not significant RR of 1.16
(95% CI = 0.97, 1.38), with less heterogeneity (I2 = 36%,
P = 0.14). Indirect comparisons, however, suggested that
longer-acting NRT (such as a nicotine patch) might be
more effective than shorter-acting types (such as a
nicotine gum and/or lozenge); RR for short-term cessa-
tion using a patch was 1.17 (95% CI = 1.00, 1.37), and
for a gum and/or lozenge was 0.82 (95% CI = 0.66, 1.02,
P = 0.009) for the difference in RRs. For longer-term
cessation the RR were (for patch) 1.26 (95% CI = 1.03,
1.55) and, for short-acting NRTs, 0.87 (95% CI = 0.60,
1.26), although the difference between the sub-groups
was not statistically significant (P = 0.09). There is good
evidence that smoking on a patch leads to higher blood
nicotine concentration than from smoking alone. However,
smoking while using short-acting NRT leads to concentra-
tions similar to that from smoking alone [9]. This difference
in response to smoking, while using these types of NRT,
might explain the apparent difference in efficacy between
patch and other NRT.
Second, we examined whether there was evidence to
suggest that preloading works because it reduces positive
or negative reinforcement from smoking and there was
modest support for this. One study [5] reported reduced
reward and one trial [10] reported no effect on positive
reinforcement. Four studies [5,10-12] reported data relevant
to negative reinforcement of smoking (feeling the need to
smoke to stave off withdrawal) and none found evidence
of this effect. However, we would expect that reduced
reinforcement of cigarettes or reduced need to smoke
should result in reduced consumption and this was
observed. In five studies [5,10,11,13,14] where partici-
pants were asked to smoke as they wanted, there was a
variable reduction in cigarettes per day, with a smaller
and variable reduction in biological markers of smoke
intake. One study, Schuurmans et al. [12], asked partic-
ipants not to change their smoking and little reduction
in consumption was noted. Studies in which partici-
pants were asked to reduce consumption showed the
largest decline in consumption [15,16]. These studies used
short-acting NRT to support reduction, which showed
no evidence of efficacy over standard NRT use. The
final part of this potential pathway is that reduced
reinforcement from smoking leads to reduced withdrawal
after cessation, but six studies showed no evidence of
this [5,10-13,16].
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preloading worked because it enhanced adherence to post-
cessation NRT. In all trials [5,10-16], nicotine preloading
was followed by nicotine post-cessation pharmacotherapy.
There is good evidence that adherence to NRT (patch or
short-acting) after quit day enhances cessation [17,18]. Four
studies reported data and none of these showed enhanced
adherence to nicotine replacement therapy in preloading
participants post-cessation [12,14-16]. As two of these
studies were ‘positive’ studies [12,14], this is good evidence
that NRT preloading does not enhance cessation through
enhanced post-quit day adherence to NRT.
Our third hypothesis was that preloading enhanced
confidence in quitting, which has been shown to be
moderately associated with enhanced cessation success
[19]. Two studies [15,16] reported contradictory data, but
this indicates no good evidence to support this hypothesis.
We concluded that there was insufficient evidence to
recommend preloading as a strategy for use routinely and
that further trials were needed to confirm effectiveness.
The best supported hypothesis was that preloading may
work by altering desire to smoke. The trials were hetero-
geneous in ways that defied easy explanation. This raises
the possibility that there is true heterogeneity in response
to preloading with nicotine patches. Some people may
benefit and others may not benefit from preloading.
Investigating mediation is important. Variation in re-
sponse to the mediator is likely to give a much clearer
signal about the efficacy of a particular strategy for preload-
ing than is longer-term abstinence, and it has important
practical implications for treatment. Instituting preloading
in the stop smoking service (SSS) would cost approximately
£50 million. If preloading was effective for only half of
users, it would be useful to know which half. If we could
monitor response to treatment (monitor a mediator), then
we might be able to stop preloading in patients who are not
responding, saving tens of millions of pounds. Alternatively,
we could use the patient’s response measured by the medi-
ator to adjust treatment (such as dose, duration, or form of
medication) to enhance efficacy.
Rationale for current trial
A further trial of nicotine preloading is required to improve
the precision of the estimate of effect of preloading, to try
and establish the cause or causes of the heterogeneity in
the current trials, and to enhance understanding of the
mechanisms and moderators of action. Preloading will be
defined as four weeks of pre-quit patch use; as our review
[8] found that patch was more effective than short-acting
NRT, and based on the potential mechanisms of action pro-
posed above, longer preloading (four weeks) is likely to be
more effective than shorter preloading (two weeks). So far
only one small study (N = 80) has tested the effect of four
weeks of nicotine patch preloading [10].Rationale for a control intervention
The control arm of this trial will not receive a placebo
treatment as the funder was keen for this trial to be
pragmatic and reflect the effect of the intervention as it
would be carried out in practice. This could lead to bias,
as participants in the control arm may feel that they are
not receiving an intervention and therefore be less likely
to continue in the trial after randomization. This could
lead to differential dropout between groups. Additionally,
a lack of treatment in the control arm could mean that
participants receive less contact or interaction with the
researcher, which itself may boost success. In order to
counteract this potential bias and to engage participants
in the control arm, we propose a minimal intervention in
the control arm, comparable to the intensity of the pre-
loading treatment, but unlikely to influence effect.
Trial objectives
To examine the relative effectiveness of nicotine patches
worn for four weeks prior to quitting plus standard NHS
care post-quit versus standard care only in smokers
undergoing NHS treatment for tobacco dependence; To
examine the safety of the nicotine pretreatment; To
examine the incremental cost-effectiveness of nicotine
pretreatment; To examine possible mediating pathways
between nicotine pretreatment and outcomes; To examine
moderators of the effects of preloading, including demo-
graphic characteristics, previous use of pharmacotherapy to
quit, smoking history, and baseline levels of dependence;.
To investigate opinions of the preloading intervention; To
assess adherence to preloading treatment and subsequent
standard smoking cessation pharmacotherapy.
Methods/Design
Plan of investigation
This is an open-label pragmatic randomized controlled
trial to compare 893 motivated to quit smokers using a
determined dose of nicotine patches for four weeks prior
to quitting, with 893 of the same type of participants ran-
domized to a control group of standard NHS treatment,
with no placebo.
Trial outcome measures
The primary outcome is six-month prolonged abstinence,
measured by the Russell standard criteria [20], defined
as a grace period of two weeks, followed by smoking
fewer than five cigarettes thereafter and biochemically
confirmed by an exhaled CO of <10 parts per million
(ppm) (primary outcome). Other measures of abstinence
are Russell standard four-week and 12-month prolonged
abstinence and seven-day point prevalence biochemically
confirmed abstinence at four weeks, six, and 12 months
(secondary outcomes). We will assess adverse events
related to NRT patch use and symptoms of nicotine
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contact. We will estimate the costs of behavioral support
and NRT, in order to calculate cost/lifetime quitter, the
cost/life year gained and the cost/quality adjusted life
year, and health service use. We will measure potential
mediators of the preloading effect, such as changes in
expired air CO between baseline and quit date, aversion
and/or nausea, dependence, ratings of smoking reward,
urges to smoke, stereotypy, confidence in quitting, and
motivation to quit. We will examine potential moderators
of the preloading effect, including demographic character-
istics, previous use of pharmacotherapy to quit, smoking
history, and baseline levels of dependence. Participants
will rate the helpfulness, whether they would recommend
preloading, and other views about the intervention. We
will record adherence to preloading in pre-quit period,
and adherence to additional standard smoking cessation
medication.
Participant entry
Sample size
893 participants in each of the two treatment groups;
1786 in total. See Figure 1 for an illustration of participants’
planned flow through the trial.
Recruitment
We propose recruiting people in the following ways:
Recruitment centers at the Universities of Birmingham,
Bristol, and Nottingham (United Kingdom) will recruit
through general practitioner (GP) surgeries. Surgeries will
be asked to write to patients who are listed as smokers on
their clinical database, asking them to call the research
team if they are interested in participating in the trial. The
letter will encourage the person to stop smoking and to
take the opportunity to enroll in the trial as a means of
doing so. The content of the letter is therefore similar
to a conversation between a GP and a patient. In some
practices, as well as or instead of sending letters (depending
on the circumstances within the practice), we will ask
practices to send out text messages to smokers advertising
the trial using their text messaging system, and will ask
them to give out fliers advertising the study with patient’s
repeat prescriptions. Again, interested patients will be
provided with the contact details of the trial team. Add-
itionally, we will give GPs referral cards detailing the
telephone recruitment number to give to their patients
who smoke, display advertising posters in GP practices,
and provide GPs with mouse mats reminding them about
the trial and to refer participants who are smokers.
Screening will take place when a potential participant
contacts the trial team to express interest in taking part.
To supplement recruitment where necessary these
three centers will also ask NHS health services such as
GP practices and NHS SSS, and community venues, ifthey have rooms for the research team to use to conduct
clinics to recruit participants from a wider area. This will
offer centralized clinic locations, and so will allow for a
wider range of advertising possibilities. We will advertise
for smokers to join the trial clinics held in these central
clinic locations using newspaper, magazine, and/or inter-
net advertisements, posters and fliers advertising the study
distributed and displayed within the community. The
study will be advertised in or alongside payslips distributed
at the recruitment centers. SSS will be asked to write to
people who have used their services in the past and are
believed to still be smokers, inviting them to take part in
the trial. Researchers will seek agreement from individual
SSS, to inform smokers booked to attend the service about
the possibility of taking part in the trial before their first
appointment. Researchers will then enroll anyone who
wishes to take part and refer them back into the SSS after
their trial treatment (preloading or coping treatment).
Recruitment centers are running a number of studies in
their university departments. In cases where participants
would be appropriate to take part in the Preloading Trial
(adult smokers not already quitting), participants will be
provided with a referral card or leaflet advertising the trial.
At the additional recruitment centre (Queen Mary
University of London, United Kingdom) participants will
be recruited at an existing smoking cessation clinic which
accepts self-, primary care-, and secondary care- referrals.
This final centre will offer patients who present to this
clinic for treatment the chance to participate in the
clinical trial, and will act as a site. Stop smoking services
commonly advertise for patients. Therefore, at this site
we will also use advertising as necessary to supplement
recruitment into the trial, as would usually take place.
Pre-randomization evaluations
Potential participants will telephone the trial office for
further details. Office personnel will give information
about the study, and if the potential participant wants
to be screened for eligibility, will then use the online
database to assign them an identification number and
perform preliminary eligibility screening. We will only ask
potential participants to provide personal contact details if
screening is successful. We will then send the potential
participant a patient information sheet and details of an
appointment at a clinic to attend for fuller discussion
with the researcher, signing the consent form, further
screening, and trial entry procedures. In three of the four
centers, we will use the participant’s own GP surgery, local
SSS clinic, or a community clinic location as the venue for
the initial meeting and this may or may not be the venue
where the participant receives NHS smoking cessation
support, depending on the surgery or service. In the
fourth centre, the initial meeting will take place in the
London-based smoking cessation clinic.
Randomised n=1786
Excluded:
Pregnant and breast feeding 
women;
Unwilling to participate;
Under 18 years of age;
Judged clinically unsuitable
Allocated to 4 week active preloading  
patch at baseline assessment
Allocated to control group (no preloading 
patch) at baseline assessment
Visit to assess adverse events & mediators
(1 week post-baseline)
Visit to assess adverse events & mediators (1 
week post-baseline)
Standard NHS smoking cessation service. 
Visits offered at: 
7-10 days before quit day
Quit day
+1 week
+2 weeks
Follow-up telephone call to assess 
mediators, adherence and opinions
at +1 week after quit day
Standard NHS smoking cessation service. 
Visits offered at:
7-10 days before quit day
Quit day
+1 week
+2 weeks
Follow-up telephone call toassess 
mediators, adherence and opinions
at +1 week after quit day
Follow ups:
4 week post quit (data obtained 
from SSS)
6 month post-quit (telephone with 
validation visit if abstinent)
Follow ups:
4 week post quit (data obtained  
from SSS)
6 month post-quit (telephone with 
validation visit if abstinent)
This service will 
either be offered 
by the trial team or 
participants will be 
referred to 
another NHS SSS 
provider.
Potential participants contacting 
trial team for more information
Figure 1 Diagram of planned participant flow through the trial.
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the inclusion criteria stated below, assessed on telephone
screening and at the baseline clinic visit:Inclusion criteria
We will include smokers (defined as regular smokers of
cigarettes, cigars, and tobacco cigarettes combined with
marijuana) aged ≥18 years of age, who, in the judgment
(see below for how judgment shall be made) of the trial
researcher, would be suitable for preloading. Smokers
must be seeking NHS support to stop smoking and
willing to quit in four weeks. They need to be able to
understand and consent to, and willing to comply with,
study procedures.Exclusion criteria
We will exclude pregnant or breastfeeding women, people
with extensive dermatitis, other skin disorder, or other
severe adverse reaction that precludes patch use. We
will exclude people who have had an acute coronary
syndrome or stroke within the past three weeks. We
will also exclude people with active pheochromocytoma
and uncontrolled hyperthyroidism.
The judgment of suitability for preloading will aim to
include more addicted smokers and exclude smokers with
such low levels of addiction that the preloading patch may
cause unacceptable toxicity. It will be based upon the time
to first cigarette in the morning with earlier use reflecting
higher addiction; number of cigarettes smoked per day
with a greater number reflecting higher addiction; higher
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of previous quit attempts despite use of appropriate
pharmacotherapy.
As all recruiting researchers will be trained stop smoking
advisors, definitive cutoffs will not be used and researchers
will use their judgment to decide suitability based on the
combination of the criteria above. In cases of uncertainty
researchers will be asked to use the following guidance
and/or consult the appropriate principal investigator.
In addition to daily smoking, two of the following must
be true: time to first cigarette after waking of less than two
hours, exhaled CO more than five ppm, or failure of more
than one previous quit attempt, despite use of appropriate
pharmacotherapy.
Withdrawal criteria
Should participants wish to withdraw from the trial, they
will be given every opportunity. It is standard practice in
smoking cessation trials to regard those who fail to attend
for support and treatment as having relapsed, which is
based on some evidence [20]. Therefore, failure to attend
will not count as withdrawal from the trial and the only
withdrawals will be those where a patient asks to be with-
drawn. Such patients will not be replaced and, unless they
refuse permission, data available up to that point will be
used. Such withdrawals are expected in fewer than 5% of
participants.
We will exclude from the trial all those who have had
severe adverse reactions previously. Given the established
safety profile of NRT and the evidence from studies of
participants using NRT while smoking [9], we do not
expect any serious adverse events due to the medication.
Nevertheless, there will be a detailed work instruction for
the trial that will detail the assessment of adverse events,
and the procedure for defining and managing serious
adverse events (SAE) and suspected unexpected serious
adverse reactions (SUSARs). In the event of a SUSAR, or
serious adverse reaction (SAR), the prescription for NRT
will be withdrawn and not reinstituted in that person. The
person will continue in the trial and be part of both the
safety and effectiveness populations.
Randomization and enrolment procedure
Randomization or registration practicalities
Participants shall be randomized to a treatment arm at
their baseline visit. They will be randomized to the
intervention or control (1:1 ratio) on the basis of a
computer-generated allocation sequence via the inter-
net, with telephone backup, which will be provided by
our electronic Primary Care Research Network (ePCRN).
This will incorporate an online case report form (CRF)
that, when basic details have been completed, will
accomplish randomization. We will block randomize par-
ticipants, stratified by centre, to account for the differencesin recruitment and treatment delivery between the London
research centre and the remaining centers. For very
rare occasions when access to the network, and there-
fore database randomization is not available, we will have a
backup process involving sequentially numbered, opaque,
sealed envelopes for randomization. Each researcher will
hold a small number of envelopes, to be used as a last
resort only.
It is common for two people, often partners, to want
to quit together. There is no imperative for the couple
to be given the same treatment as one another, as the
absence of a placebo means mixing up medication is
unlikely, and not randomly allocating a person to the same
intervention as their partner may introduce clustering
effects. Therefore, in these cases we will consent for each
member of the couple to be randomized individually,
and will randomize each individually using the standard
allocation procedure used for all other participants.
Study procedures
Trial treatment providers
The provision of participant treatment in the trial shall
be carried out by researchers from both a clinical and
non-clinical background. All shall be trained by the NHS
SSS and the National Centre for Smoking Cessation and
Training (NCSCT) to provide stop smoking support and
to advise and provide all pharmacotherapies available
through the NHS SSS. This is the maximum equivalent
to what is required for NHS SSS advisors. In addition to
this all researchers will be provided with trial specific
and Good Clinical Practice (GCP) training. However, in the
case of any uncertainty (regarding suitability for inclusion)
researchers will be able to contact the principal investigator
(PI) for the relevant site, for clarification by telephone. If
the PI for the relevant site is not contactable then they shall
contact another of the trial PIs. PIs will only delegate tasks
relevant to the researchers’ training and experience.
Provision of standard NHS SSS support
In addition to the research visits carried out below, all
participants will receive standard NHS SSS support and
medication whilst enrolled in the trial. One of the centers
involved in this study (Queen Mary University of London,
London) hosts an existing NHS SSS clinic operating
within the East London SSS. All participants recruited
through this site will be provided with both trial sup-
port and treatment, and standard NHS SSS support and
treatment by the research team. Therefore, participants
will be booked in for standard support at the baseline
trial visit. The remaining three centers will be recruiting
through GP practices and local SSS across a number of
trusts. In some trusts and practices it may be most favor-
able (where local funds allow and a service is not already
provided within the GP practice) for the research team to
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(acting on behalf of the local NHS SSS, as above), whereas
for others it may be most favorable to refer participants to
their local SSS for their standard treatment (where local
funds do not allow and a local service convenient to the
patient is provided). In which case the research contacts
described below would be carried out by the research
team and the standard support by the SSS. In cases such
as this researchers will book participants into a local SSS
clinic at the baseline research visit, and a link will be made
with the local SSS requesting the date of quit day and
four-week quit data for the participants concerned. In a
previous trial this has been achieved by requesting reports
from the SSS, however more and more services are using
a centralized database, which the trial team will request
access to. Consent will be requested from participants to
access their SSS records. Where appropriate, where the
study team will only be conducting research activities
and will not be providing any standard NHS support,
GP practices, and SSS may be asked to act as participant
identification centers (PICs) only. In this case GPs will be
asked to inform their patients who are smoking about the
trial and ask if they would like to take part (as described
previously), and in some cases asked to hire a room out
to the study team, which will be used to carry out the
research activity.Research contacts
Visit 1 - baseline - enrolment
The purpose of this visit is to explain the trial and seek
written consent for any further trial procedures. These
includes further screening for participant eligibility and
randomization if the participant is eligible. The researcher
will also collect basic data, take relevant samples, and dis-
pense the preloading and provide support to enhance
adherence to NRT (in the preloading arm only). Data
to be collected by the researcher at this visit is reported
in Table 1.Visit 2 - one week after enrolment
The purpose of this visit is to examine adverse events to
see whether they are due to preloading in accordance with
GCP, to collect a measure of exhaled carbon monoxide
(CO), to assess adherence to preloading in the preloading
trial arm, to collect a salivary sample for cotinine measure-
ment and measure other potential mediators (as on visit
1). If this visit reveals problems with adverse events or
requires alteration of the dose of the preloading patch,
further visits and/or telephone calls will be scheduled
as seems appropriate to the researcher or PI.
In the control group, this visit has no therapeutic or
safety purpose and is there solely for us to collect data.
We therefore propose to compensate all participants forreturning for this visit with £15 for travel expenses and
the time involved.
Every effort will be made for this visit to take place
exactly one week after baseline; however in cases where
this is not possible, visit 2 will take place between week −3
and week 0, before data is classed as lost to follow-up.
Telephone call one week after quit day
During this telephone call from the researcher to the par-
ticipant, potential mediators will be measured (as at visit 1),
as well as adherence to the nicotine patches during the pre-
loading period, and opinions of the preloading intervention.
Every effort will be made for this contact to take place
exactly one week after each participant’s quit day; how-
ever in cases where this is not possible this contact will
take place between 5 days after quit day and week 4, before
data is classed as lost to follow-up.
In some cases a participant may reach their quit date
and fail at this attempt. In this case participants may
reset their quit date. However as per NHS SSS guide-
lines this reset quit date would be classed as a new quit
attempt by the service. Therefore, for the purposes of
this study the original quit date will be classed as the
quit date, and this date will inform follow-ups.
Four week follow-up
As described above, in some cases quit data from this
follow-up will be collected by the research team, how-
ever in other cases it will be collected by SSS operating
outside of the trial. In the latter case we will set up a system
with the local SSS to gain access to this data. Smoking
abstinence at four weeks is defined as no smoking at all
in the past two weeks, confirmed by CO <10 ppm.
Six month telephone and clinic follow-up
We will telephone participants six months after their quit
day to establish abstinence and measure relevant media-
tors. Participants who declare abstinence will be invited to
return to clinic for exhaled CO measurement to confirm
this. As this is not a therapeutic visit, participants return-
ing for the visit will be compensated £15 in lieu of travel
expenses.
Every effort will be made for this contact to take place
exactly six months after each participant’s quit day; how-
ever in cases where this is not possible this contact will
take place between two weeks prior to six months post-
quit and month nine, before data is classed as lost to
follow-up.
12 month telephone follow-up
All measures as for six month follow-up and participants
attending will be compensated £15 in lieu of travel
expenses.
Table 1 Data collection to take place at the baseline visit
Demographics Basic demographic information (date of birth, gender, ethnic group, educational qualification, occupational
classification),
Additional baseline measures to allow future assessment of predictive ability of variables on weight change
from baseline to follow-up:, heaviest weight to date, weight gain. For more information on investigation of
weight gain see Additional file 2.
Medical history Medical problems and concomitant medication.
Healthcare usage data Baseline healthcare use (including primary care and secondary care visits) for economic analysis.
Mediators Baseline measures to allow future assessment of change in potential mediators of the preloading effect,
such as dependence, nausea from smoking, reward from smoking, urges to smoke, smoking stereotypy,
confidence in quitting, motivation to quit.
Past smoking and quitting history Information on smoking history (cigarettes per day, age at commencement, dependence, longest period
of previous abstinence), and exhaled CO.
Additional baseline measures to allow future assessment of predictive ability of variables on weight change
from baseline to follow-up: cigarettes per day, alcohol intake, previous quit attempt.
Previous use of pharmacotherapy for cessation and experiences of doing so, to assess suitability for treatment,
and to examine whether it moderates the effectiveness of preloading.
Biological samples
and measurements
Blood sample to identify genetic information (this will only take place at research centers with the resources
to do so, where researchers are trained in phlebotomy, and will be optional for participants). For more
information on genetic investigation see Additional file 1.
Weight, height Participant weight recorded using self-report and weighing scales. As people who relapse will
not attend clinic at 6 and 12 month follow-ups the difference between self-reported and measured weights
will be applied as a corrective adjustment to self-reported weight at follow-up in these participants. For more
information on investigation of weight gain see Additional file 1.
Salivary sample to measure cotinine concentration (the best measure of smoking intensity).
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exactly 12 months after each participant’s quit day; how-
ever in cases where this is not possible this contact will
take place between two weeks prior to 12 months post-
quit and month 15, before data is classed as lost to
follow-up.
At the time of booking baseline, 6 month and 12 month
clinic visits participants will be sent an appointment letter
with the date, time and location of their appointment. In
addition participants will be sent a reminder text 24 hours
before each clinic visit (visit 1, visit 2, 6 month, 12 month)
to help to ensure that they remember the appointment
and maximize follow-up rates.
Treatments
Treatment arms
Intervention The active intervention is a 21 mg Niquitin
CQ Glaxo Smith Kline Consumer Healthcare (Beecham
Group PLC, 980 Great West Road, Brentford, Middlesex,
TW8 9GS, United Kingdom) nicotine patch. Participants
will wear these for four weeks before their smoking quit
day, from the day of their enrolment. They will be advised
to wear the patch for 24 hours a day. Participants will be
advised to smoke as normal and avoid reducing consump-
tion, during pre-quit patch treatment. Allowing nicotine
concentrations to fall may mean cigarettes will be more
rewarding, undermining suspected mechanisms [21]. We
will help participants plan to keep to their consumption,
for example by asking a 20-per-day smoker to make surethey empties their pack by bedtime if possible. However,
participants will be free to reduce and not pressured to
smoke if they find this difficult.
Although we aim that participants shall preload for
four weeks, in some cases we will need to book participants
into convenient NHS stop smoking clinics in order for
them to also receive standard NHS smoking cessation
support, and some participants defer their quit date.
Consequently, participants will be booked into cessation
clinics to seek to ensure a target quit date between
three and five weeks after enrolment. In the event that
a participant has not yet reached their quit date but
wishes to delay it (in particular, this may occur in the
case of personal difficulties that the smoker feels will
seriously impair their chances of being successful) then
the participant will be able to delay their quit date to a
maximum of eight weeks following their baseline appoint-
ment, and will receive a maximum of eight weeks’ worth
of nicotine patches for preloading.
The manufacturer, GlaxoSmithKline plc (GSK) (T/A
GlaxoSmithKline Consumer Healthcare, Brentford, TW8
9GS) will deliver the medication to the trial centers. This
is an open-label RCT where medication is dispensed in
clinics operating within the NHS and therefore there are
no special labelling or packaging requirements. Medication
will be labelled and packaged as for normal clinical use and
stored at the centers in facilities that meet the requirements
of GCP. A risk assessment will take place to check the
facilities for storage of the medication, to ensure that
Lindson-Hawley et al. Trials 2014, 15:296 Page 9 of 18
http://www.trialsjournal.com/content/15/1/296the drug will remain stable and will be stored securely,
on a centre by centre basis. If the risk assessment deems
it necessary we shall keep temperature logs to monitor
the environment in which the medication is kept. The
researchers (trained in smoking cessation treatment and
medications) will dispense the medication in accord with
the protocol and will record the batch numbers on the
CRF, as is common practice in the NHS. Each person will
usually be dispensed two weeks of patches initially, which
is sufficient to cover treatment to the second visit but
allows extra should that visit be missed. At the second
visit (one week after baseline), we will usually dispense
three more weeks of medication to allow up to five
weeks of preloading. The researcher will be able to use
some discretion when dispensing the number of patches
needed, for example to allow for cases where participants
undertake a lot of exercise and so patches are likely to fall
off and need replacing more commonly. The participant
will not pay a prescription charge for the medication as
the medication will be donated free of charge by GSK.
If participants have patches left over when they reach
their quit day and they are not using nicotine patches as
part of the standard NHS post-quit treatment we will
encourage them to use up their patches after quitting.
The rationale behind this is that otherwise we will be
asking participants to stop using their patches when they
are most vulnerable (on their quit day), which could
contribute to failure to quit.
Control This trial will be open label, and the comparator
to preloading will be standard stop-smoking treatment,
with no other intervention. After the participant is ran-
domized to no intervention, they will begin a four-week
period prior to their quit date where NRT will not be
used to allow comparison with the intervention arm.
Participants will not be advised to change their smoking
behaviour in any way. The control arm will also be
referred to standard smoking cessation support at the
first visit, where necessary.
Trial behavioral support In both trial arms researchers
will provide behavioral support. In the preloading arm,
when preloading patches are dispensed at the baseline
visit, the researcher will provide support - explaining the
rationale as to why nicotine preloading might be helpful,
how to use the patches, including helping participants to
set reminders to use the patch, providing evidence on
safety and tolerability of preloading, common side-effects
and how to deal with them - as well as supply a booklet
describing the rationale of preloading treatment, with
the aim to enhance adherence. At the second visit, the
researcher will enquire about participants’ understanding
of the necessity of using preloading and ask about their
concerns and address these as appropriate. In the controlarm, participants will not be provided with this in-depth
information about preloading, but will be provided with
comparative counselling. This will involve asking partici-
pants to think about the cigarettes they smoke, what
triggers these, and which they find most rewarding, and
will be accompanied by a comparable booklet explaining
the theory behind cue-associated learning.
Standard SSS support Standard smoking cessation sup-
port will not be altered in the intervention group by the
previous preloading. Support typically commences one
to two weeks prior to a target quit date and provides
behavioral support on quit day, and then weekly until
four weeks afterward. This support addresses issues such
as planning for the quit day, the ‘not a puff rule’, and how
to deal with difficult situations. It also provides monitor-
ing of behaviour and validation of abstinence through CO
testing. SSS providers have training to provide this behav-
ioral support, largely modelled on withdrawal-orientated
therapy [22]. This behavioral support for cessation will
begin two to three weeks after the commencement of
preloading treatment so that the target quit date is three
to four weeks after commencement. Pharmacotherapies
provided as part of this support are either NRT, vareni-
cline, or bupropion and SSS involved in the trial will be
informed that they should provide these to participants
as is usual.
Dose modifications for toxicity
Twenty-four hour patches can lead to problems of night
time wakefulness or vivid dreams. Participants will be
warned of this and anyone who has suffered from this
in the past (assessed at baseline) will use the patch for
16 hours per day initially. In addition, we will warn par-
ticipants to use the patch during daytime only should
they suffer from difficulty sleeping. There is no evidence
that 24 hour patches are more effective than 16 hour
patches for cessation [6] and no reason to assume that the
effectiveness of preloading depends upon 24 hour wear.
NRT has been shown to be safe and there are no plans to
modify the dose of NRT dispensed in the intervention
group. However the dose of the patch may be reduced
(to 14 mgif the participant reports previous experience
of adverse reactions to a 21 mg patch and is not prepared
to start 21 mg patches, the participant has symptoms
of nicotine overdose (these include nausea, increased
salivation, and pounding heart), or the participant wishes
to reduce the dose because of presumed adverse effects
attributed to the patch.
The intervention will be stopped and not reinstituted
if the participant no longer wishes to use the preloading
and/or decides not to proceed to a quit attempt, clear
symptoms or signs of nicotine overdose are observed, not
remedied by reduced dose of patch or reduced smoking
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heart), the participant has some intervening health state
that makes continued intervention impossible, for example
admission to intensive care unit, a contraindication to
this kind of NRT use or exclusion criterion emerges,
for example the participant discovers she is pregnant.
The intervention may be temporarily halted and re-
started. This may occur if a participant has an intervening
health or emotional crisis, such as admission to hospital
as an emergency, or a bereavement. It is likely that an
intervening period of smoking off the patch is likely to
remove any benefit from prior preloading. In this circum-
stance, the participant could choose to start the preloading
again, which will be allowed once. For the purposes of
counting abstinence, the quit day will be deemed to have
been reached a maximum of eight weeks after the baseline
visit, even if the participant is continuing with preloading
and has not reached quit day at this point. If we lose
contact with a participant and they do not make a quit
attempt, this will not count as temporary halting of pre-
loading and for the purpose of counting abstinence
their quit day will be deemed to have taken place four
weeks after the baseline visit.
In cases where the participant quits before their planned
quit day, this day will be classed as the day they actually
quit and the timing of follow-ups will be informed by this
date, rather than the date originally planned.
Concomitant medication
All medications will be permitted for use concurrently
with preloading except those that are proven to help
smoking cessation (bupropion, nortriptyline, mecamyl-
amine, reserpine, and varenicline). These will be permitted
for use in the latter part of preloading in preparation for a
quit attempt, but not throughout preloading. The NHS
clinic will either prescribe or arrange prescription of one
of three first line smoking cessation pharmacotherapies:
bupropion, varenicline, or NRT (used as a single form or
combination NRT) at the dose that they see fit. Bupropion
and varenicline should normally commence no sooner
than two weeks and at least a week prior to the quit day
initially set by the SSS as is standard, and standard NRT
use commences on quit day. The choice of medication
will be determined by the smoking cessation advisor
and patient in consultation and bearing in mind guidance
from the English body that sets guidelines (NICE) on
choice. The NHS medication can continue for as long as
the cessation advisor prescribes, with no special restriction
imposed by the trial protocol.
NICE guidance advises against concurrent use of NRT
and varenicline. However, this is due to the illogicality of
the combination in normal post-cessation support, rather
than evidence of safety concerns [23]. Concurrent use will
have to happen in this trial if preloading is followed byvarenicline post-cessation support. It is possible that NHS
personnel would be more inclined to prescribe varenicline
in the control arm than in the intervention arm, especially
as patients may be comfortable and ‘responding’ to NRT.
We will counter this in several ways. We will give a letter
to the participant to give to the SSS therapist to explain
the trial and to encourage free use of medication including
varenicline. Second, we will monitor this issue and investi-
gate corrective actions if we see it happening with particu-
lar SSS therapists or services. Third, we have addressed
this in the analysis plan by proposing a sensitivity analysis
to adjust for post-cessation medication use.
Data on all concomitant medication will be recorded.
There is no special dietary or lifestyle advice that is
imposed by using NRT and the associated regimens for
using it proposed in this protocol.
Trial management
Trial steering committee
We propose a trial steering committee (TSC) with aca-
demic, primary care practitioner, and independent mem-
bers. We will also incorporate a volunteer from a smokers’
panel group. The UK Centre for Tobacco and Alcohol
Studies (UKCTAS) has a smokers’ panel to give smokers’
views on research priorities and projects. We will also
incorporate an NHS service manager, to give NHS service
views.
Data monitoring committee
Following guidance on open-label and low-risk trials, we
have agreed with the funder (National Institute for
Health Research, Health Technology Assessment pro-
gram (NIHR HTA)) that a data monitoring committee is
not necessary.
Pharmacovigilance
For information regarding the assessment of participant
safety and reporting procedures please see Additional file 1.
Assessment and follow-up
Assessment
The primary and secondary outcomes will be measured
as detailed in the previous ‘Trial design’ section. Further
outcomes shall be assessed as follows:
At baseline, the researchers will collect the information
stated in Table 1. Educational qualification and occupa-
tional classification will be classified in categories used in
the UK Census 2011 [24], ethnic group will be classified
according to categories used by the NHS SSS, based on
the UK Census 2001, and exhaled CO will be measured
using a CO monitor, as a measure of smoke intake.
Potential mediators of the preloading effect will be
assessed at baseline, one week later during the pre-quit
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after quit day.
Dependence will be measured at baseline using the
Fagerstrom Test for Nicotine Dependence (FTND) [25].
The FTND will be re-administered at the week following
baseline visit, and at six and 12 month follow-ups. How-
ever, for the purposes of the analysis we will exclude
the cigarettes per day item, which might reasonably be
expected to decline in the active patch group without
necessarily indicating reduced dependence.
Changes in reward from smoking, measured using the
modified Cigarette Evaluation Questionnaire (mCEQ) [26],
will be measured at all contacts (at post-quit contacts this
will only be in those who have returned to smoking). We
will ask the participant to focus on the cigarette after the
evening meal (or equivalent in shift workers). For those
who smoke after quit day, we hypothesize that preloading
may result in decreased reward from smoking. The mCEQ
measures satisfaction, taste, mood, cognitive, and sensory
sensations to smoking particular cigarettes. At pre-quit
contacts we will also use two simple, single item rating
scales which provided more useful data than the mCEQ
in our trial of varenicline preloading [27]. These ask
participants to rate ‘Have you found your urges to
smoke stronger or weaker than usual in the last week’
with response options of ‘Much stronger; slightly stron-
ger; same as before; slightly weaker; much weaker’; and
‘Have you found cigarettes more or less enjoyable than
usual in the last week?’ with response options of ‘Much
more enjoyable; slightly more enjoyable; same as before;
slightly less enjoyable; much less enjoyable’. We hypo-
thesize that preloading would reduce satisfaction and
the degree to which it does might be associated with
improved outcome.
We will also measure changes in urges to smoke, mea-
sured using the urge strength and frequency questions
from the Mood and Physical Symptoms Scale (MPSS)
[28], at all contacts. These questions are both strongly
correlated with the FTND, and predict successful smoking
cessation more strongly than the FTND or other alterna-
tives, such as the Questionnaire of Smoking Urges (QSU)
[29,30]. Changes in stereotypy (a measure of the degree to
which smoking is prompted by cues to smoke) will be
measured using a subsection of the Nicotine Dependence
Syndrome Scale (NDSS) [31], at baseline and the visit one
week after baseline. Only two questions from this scale
will be used as the other questions in the scale are either
forced to change if cigarette consumption drops or could
not be assessed over a short period.
Two variables that we do not expect to mediate the
relation between preloading and abstinence will be mea-
sured. These are confidence in quitting and motivation to
quit. They are often presumed to be mediators of smoking
cessation success, but the effects have been found to bemuch less than supposed [19], so we will test this em-
pirically. They are measured by single items only, using
standard wording. These are: “How high would you rate
your chances of giving up smoking for good at this
attempt?” and “How important is it to you to stop smok-
ing for good on this attempt?” (with response options of
‘Not at all; a little; somewhat; very; extremely, in both
cases). These variables will be measured at baseline and
after the first week of preloading.
Smoking consumption will be assessed at each contact
using cigarettes per day, measured using self-report and/
or changes in exhaled CO (to assess changes in smoke
inhalation). This will be used to assess whether consump-
tion reduces prior to quitting and to establish whether
relapsed participants smoke less than at baseline or return
to their previous consumption.
Aversion to smoking will be measured at baseline, the
week following baseline, one week post-quit, and at six
and 12 month follow-ups. Interviews with participants
taking part in a previous trial [32] where participants
were asked to use nicotine patches for two weeks whilst
still smoking found that a number of participants thought
that preloading worked because it made smoking aversive;
for example by creating nausea and/or making a partici-
pant lose the will to smoke. This made some participants
keen to quit. Therefore, we will test whether participants
do find smoking aversive whilst using patches, and if so,
for how long this effect persists. Interview participants’
responses suggest that markers of aversion are loss of the
will to smoke and nausea. We are already measuring urges
to smoke using the Mood and Physical Symptoms Scale
[28]. We will measure nausea by asking participants to
indicate the extent to which they have experienced nausea
in the following circumstances: when they have seen
cigarettes, lighters, or other smoking paraphernalia, and
when they have smelt cigarette smoke. These situations
were chosen as they are likely to be applicable to both
participants who are smoking and those who are abstin-
ent. Alongside this, at their visit one week after baseline,
participants will be asked about the ease with which they
are smoking alongside the patch. After being asked how
many cigarettes per day they are smoking participants will
be asked: ‘Have you had to force yourself to smoke these?’
(response choices: Yes or No), and ‘If so, to what extent?’
(responses range from ‘Very much so’ to ‘Not at all’).
We will assess the extent to which participants adhere
to the preloading treatment at the visit one week after
baseline and one week after quit day. As the time between
these two visits will be at least a month participants will
be given a simple means with which to record whether
they have put their patch on each day. This will not be
returned to the trial team but can be used as a memory
aid by participants when reporting their adherence to the
researcher. Potential side-effects of NRT patch use will
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line assessment, and one week post-quit.
At the end of the first week after quit day, participants
will be asked about their experiences of preloading. Their
response will be recorded by ticking simple emergent
categories that apply. These will be based on responses
given in a recent interview study conducted as part of the
Rapid Reduction Trial [32] and will include categories
such as: ‘Did not feel urge to smoke’, ‘Smoking rate
reduced’, and ‘Felt no effect of preloading’. They will also
be asked to rate the helpfulness of the intervention, and
whether they would recommend it to somebody else by
answering the following questions: ‘How helpful did you
find the preloading intervention?’ (answers rated on a
scale from ‘Very helpful’ to ‘Not very helpful’), and ‘Would
you recommend the preloading intervention to somebody
else?’ (response choices: ‘Yes’ or ‘No’).
We will assess participants’ use of health services (includ-
ing primary and secondary care) during the preloading and
follow-up periods, so as to assess whether the intervention
might have caused an increase in use (see cost-effectiveness
analysis).
Researchers will obtain saliva samples to measure sal-
ivary cotinine concentration at baseline (while smoking
only), and one week after enrolment (while smoking and
using or not using nicotine patch). Following advice from
the funder, funding for the analysis of cotinine samples is
not available. We will seek this separately, when the study
has been completed. If there is no effect of preloading
then analysis of saliva samples will not be beneficial, and
so will not proceed.
Observational investigations are also planned and are
detailed in Additional file 2.
Loss to follow-up
In accordance with the Russell Standard [20], we will
conduct an intention-to-treat analysis, and assume those
lost to follow-up are smokers. We will make three attempts
to contact participants using their preferred method before
an attempt at follow-up is abandoned.
Trial closure
The end of the trial is defined as the last date of follow-up
of the last patient, following database lock. However at
present there is uncertainty as to when the last follow-up
will take place. We will conduct a futility analysis with the
aim of saving the resources of the funding body (NIHR
HTA). The futility analysis will take place 30-months post
the commencement of recruitment, or as soon there-
after as possible, when all the primary outcome data
are collected. The analysis will examine the difference
between arms in the frequency of occurrence of the
primary outcome (six month follow-up data). If there is a
lack of significant effect (P <0.05) at six month follow-up,then the 12 month follow-up shall be terminated and the
study will close 36 months after commencement. If there
is a significant difference in six month abstinence then
12 month follow-up will be completed, taking the study to
42 months duration.
Statistics and data analysis
Sample size
This is determined based on plausible estimates of the six
month confirmed prolonged abstinence rate in the control
group and the effectiveness of preloading. A recent trial
showed a six month abstinence rate of 15% [33]. Another
trial of 631 participants also found a similar prolonged
abstinence rate [34]. We have therefore settled on an
abstinence rate in the control group of 15%. Our meta-
analysis found summary RRs of 1.05 for short-term and
1.16 for prolonged abstinence [8]. However, there was
heterogeneity, perhaps explained by use or non-use of
the patch, but other differences between trials make this
uncertain. It is therefore difficult to settle on a specific
RR, but we chose 1.4 as plausible and an effect likely to
interest the NHS SSS. The RR (95% CI) for abstinence
in the patch trials in our review [8], was 1.17 (1.00,
1.37) for short-term and 1.26 (1.03, 1.55) for long-term
abstinence, but with unexplained heterogeneity, so our
RR appears reasonable. For example, an RR of 1.4 means
that the summary effect for NRT is about 2.2, similar to
that for varenicline versus placebo (2.3) [3]. This gives us
a sample size of 893 participants per arm or 1786 in total
for 90% power, calculated with Yates correction using
nQuery (Statistical Solutions Ltd, 4500 Airport Business
Park, Cork, Ireland) (Table 2).
Analysis plan
The primary analysis will be performed using the full
(intention to treat) dataset, including all those random-
ized, presuming that those who do not provide data at
follow-up are continuing to smoke. We will compare
the proportion of people achieving the primary outcome
by calculating the RR and 95% CI. These figures allow
clinicians to have an intuitive sense of the size of the
effect. However, the primary effectiveness analysis will be
based on an adjusted OR, calculating first an unadjusted
OR (for comparison), and then an adjusted OR. We
will adjust for two the precision of the treatment effect
estimate, using multiple logistic regression in Stata
(StataCorp LP, 4905 Lakeway Drive, College Station,
Texas 77845-4512, USA) the length of previous abstinence
achieved and baseline urges to smoke (using the urges
questions from the MPSS), which have both been shown
to be predictors of success [29,30,35]. In a sensitivity
analysis, we will also adjust for post-cessation medica-
tion use, because varenicline is more effective and this
might be imbalanced across treatment arms. Secondary
Table 2 Sample sizes required for different combinations
of power and relative control versus intervention
six-month abstinence rates
Trial with
80% power
Trial with
90% power
% prolonged
abstinence
in control
% prolonged
abstinence in
intervention
Number/arm Number/arm
RR = 1.3
14 18.2 1249 1655
15 19.5 1150 1524
16 20.8 1064 1409
20 26 805 1065
RR = 1.4
14 19.6 734 970
15 21 676 893
16 22.4 625 825
20 28 471 622
RR = 1.5
14 21 490 646
15 22.5 451 594
16 24 416 549
20 30 313 412
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considered statistically significant. We will calculate the
proportion of people finding the intervention helpful,
but not compare these between arms with inferential
statistics.
The safety analysis will be performed on all participants
who complete follow-up at one week following baseline
or follow-up one week after quit day. We will examine
the occurrence of moderate and severe AEs and SAEs,
and compare between trial arms. We will also code
events using the MedDRA coding database to examine
the specific problems that might occur with preloading.
We will relate these to baseline characteristics and
changes in smoking behaviour, to investigate predictors
of adverse events. The analysis will be performed in
Stata using logistic regression.
The mediation analysis will proceed using the proced-
ure outlined by MacKinnon, using regression modelling
[36]. We will estimate the mediated effect using mediation
regression equations, modelling the association between
abstinence (dependent variable) and intervention, and
between abstinence (dependent variable), the intervention
and the potential mediators, in both cases using logistic
regression. The association between (continuous) mediators
and the intervention will also be modelled using linear
regression. The mediated effect will be estimated by the
product of coefficients method, using the appropriate
coefficients from the regression models, and using boot-strapping to compute confidence limits of the mediated
effect. We also propose a two-step mediation process,
whereby preloading leads to higher nicotine concentration
(reflected by cotinine concentration), which in turn leads
to reduction in measures of dependence that lead to
improved abstinence. We will examine this using Mplus
(Muthén & Muthén, 3463 Stoner Avenue, Los Angeles,
CA 90066) with a structural equation model.
We will conduct exploratory subgroup analyses to exam-
ine whether the effect of preloading is similar for people
who use varenicline or those using NRT (we expect the
proportion using bupropion to be small), first testing
for effect modification with a multiplicative interaction
term in logistic regression. Similarly we will examine
whether the effect of preloading is modified by depend-
ence level (assessed by FTND, exhaled CO, and salivary
cotinine), demographic characteristics, previous use of
pharmacotherapy to quit, and smoking history. We will also
investigate the proportions of reactors and non-reactors
to the preloading treatment (those who do and/or do
not experience reductions in CO, cigarettes per day and
cigarette reward, between baseline and the visit one
week following this), whether quit rates differ between
these two groups, and whether this is modified by the
pharmacotherapy participants are provided with from
the NHS SSS.
We aim to address two aims concerning weight gain
during a cessation attempt, details of the analysis plan
for these can be found in Additional file 2.
Cost-effectiveness analysis
Cost-effectiveness analysis will be conducted by combin-
ing data collected within the trial and existing models.
We will calculate the proportion of prolonged abstinent
participants produced by the intervention. We will esti-
mate the costs of the behavioral support and NRT using
a similar approach adopted in our previous HTA reports
and economic modelling [37,38], using local costings where
appropriate. These models will enable the calculation of the
proportion of lifetime quitters, the cost/lifetime quitter, the
cost/life year gained and the cost/quality adjusted life year.
We will compare the health service use for the active
and control groups to assess whether preloading leads
to extra health service use. Longer term NHS costs can
be estimated using a cost model recently developed by
the Public Health Research Consortium (PHRC), involving
one of the investigators [39]. Cost effectiveness acceptabil-
ity curves will be used to demonstrate the value for money
based on a range of threshold values for a quality-adjusted
life year (QALY).
Data handling, record keeping, and retention
The secure online database used for trial identification
number allocation and randomization will incorporate
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of each CRF (the source documents for the trial). This is
because the CRF will need to be completed to correspond
with each clinic visit and follow-up; however there may
not always be access to a computer or internet connection
when trial clinics are taking place. In this case the paper
CRF will be completed and data will be copied to the
online version at a later date. CRFs will be kept in a
locked cabinet in a secure office and department. These
will be transferred from the site of the research visits to
the universities personally by the researchers, and consent
will explicitly be sought from participants to do so. The
trial database will be securely developed, held and main-
tained by the Primary Care Clinical Research and Trials
Unit (PC-CRTU) at the University of Birmingham. On
completion of the trial and data checking, the CRFs
will be transferred to a secure, GCP compliant, external
archiving facility, where they will be held for 15 years and
then destroyed. The database will be anonymized and a
secure compact disc containing the link between identifi-
cation number and patient identifiable information will be
stored in a secure archiving facility.
The trial is being run as part of the portfolio of trials
in the Primary Care Clinical Trials Unit (PC-CTU), a
National Institute for Health Research (NIHR) recognized
trials unit in Primary Care Health Sciences, at the Univer-
sity of Oxford. The data management will be run in accord
with the standard operating procedures, which are fully
compliant with the Data Protection Act and GCP.
Patient identifiable data will be shared only within the
clinical team, on a need-to-know basis, to provide clinical
care and ensure good and appropriate follow up. Patient
identifiable data may also be shared with participants’ GPs
and approved auditors from the REC, NHS Research and
Development, or the MHRA. Otherwise, confidentiality
will be maintained and no one outside the trial team
will have access to either the CRFs or the database.
Safety monitoring plan
Risk assessment
A risk assessment has been carried out in accordance
with MHRA guidance on Risk Adapted Approaches to
Monitoring. A suitable monitoring plan will be drawn up
and appropriate on-site and central monitoring will be
performed.
Monitoring at the study coordination centre
The trial will be conducted in accordance with the risk as-
sessment, monitoring plan, current approved protocol, GCP,
relevant regulations, and standard operating procedures.
Monitoring will be performed by the University of
Oxford’s Clinical Trials and Research Governance (CTRG)
Office according to CTRG standard operating procedures
and GCP. Data will be evaluated for compliance with theprotocol and accuracy in relation to source documents.
Following written standard operating procedures, the
monitors will verify that the clinical trial is conducted
and data are generated, documented, and reported in
compliance with the protocol, GCP, and the applicable
regulatory requirements.
Data cleaning will take place by a series of logical checks
on the electronic data (for example, a person cannot be
recorded as a prolonged abstinent smoker at six months if
they were not in such a state at four weeks). Discrepant
records will be checked with the source documents and
the database amended if necessary.
The trial may be subject to monitoring by the lead
Comprehensive Local Research Network (CLRN). Direct
access will be granted to authorized representatives from
the Sponsor, host institution, and the regulatory authorities
to permit trial-related monitoring, audits, and inspections.
Therefore, participants will be asked for consent to allow
their records to be viewed by these authorities.
Monitoring at local sites
The monitor will perform site visits. The team will be
trained in all aspects of the protocol and trial procedures,
and the monitor will check this as a part of their visit
(compliance to protocol, delegation logs and curriculum
vitae).
Serious breaches
The Medicines for Human Use (Clinical Trials) Regulations
contain a requirement for the notification of ‘serious
breaches’ to the MHRA within seven days of the Sponsor
becoming aware of the breach.
A serious breach is defined as ‘a breach of GCP or the
trial protocol which is likely to affect to a significant degree:
a) the safety or physical or mental integrity of the
subjects of the trial; or
b) the scientific value of the trial’.
In the event that a serious breach is suspected the
Sponsor must be contacted within one working day. In
collaboration with the CI, the serious breach will be
reviewed by the Sponsor and, if appropriate, the Sponsor
will report it to the REC, MHRA, and the NHS host
organization within seven calendar days.
Regulatory issues
This study has CTA from the UK competent authority-
the MHRA (CTA 21584/0322/001-0001) and has approval
from the National Research Ethics Service Committee
East Midlands - Leicester (REC reference: 12/EM/0014).
The CI will ensure that this trial is conducted in accord-
ance with the principles of the Declaration of Helsinki and
with the ICH Guidelines for Good Clinical Practice
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a year throughout the clinical trial, or on request, an an-
nual progress report to the REC, host organization, and
Sponsor. In addition, an end of trial notification and final
report will be submitted to the MHRA, the REC, host
organization, and Sponsor.
Patient consent
The process for obtaining participant informed consent
will be in accordance with GCP. The researcher and
the participant shall both sign and date the consent
form before any trial procedures begin.
A copy of the signed form will be kept by the partici-
pant, and the original will be retained in the appropriate
site file. Another copy will be forwarded to the GP to file
in the participant’s medical notes.
The participant’s decision to take part in the trial is
entirely voluntary. It will be explained to potential partici-
pants that they can withdraw consent at any time without
penalty or affecting the quality or quantity of their future
medical care.
Participants will be informed of any relevant information
that becomes available that affects their participation in the
study. Revised consent forms will be used if applicable, and
amended forms will be submitted to the main REC for
favorable opinion prior to use. Revised informed consent
forms will be signed by the parties specified above.
Indemnity
The University of Oxford has a specialist insurance policy
in place which would operate in the event of any partici-
pant suffering harm as a result of their involvement in
the research (Newline Underwriting Management Ltd,
at Lloyd’s of London, policy number: WD1200463). NHS
indemnity operates in respect of any clinical treatment
which is provided.
Sponsor
The University of Oxford will act as the Sponsor for this
trial. The Sponsor’s office can be contacted at: Clinical
Trials and Research Governance, Joint Research Office,
Churchill Hospital, Oxford, OX3 7LE.
Funding
The NIHR HTA program is funding this trial. The appli-
cation for funding was made in response to a themed
call by the HTA program.
Audits
The trial may be subject to inspection and audit by the
University of Oxford (under their remit as Sponsor), the
study coordination centre and other regulatory bodies,
such as the MHRA, to ensure adherence to GCP.Financial arrangements
Participant payments
Participants will receive payment for travel and inconveni-
ence at the following visits: one week post-enrolment - £15
to intervention and control groups, Six month clinic follow
up - £15 to intervention and control groups, and 12 month
clinic follow up - £15 to intervention and control groups.
GP payments
No payments will be made to GP surgeries or NHS SSS
providers, aside from NHS service support costs, as agreed
with the Primary Care Research Network (PCRN).
Discussion
The proposed study is warranted due to the uncertainty
of the effect of nicotine patch preloading. The RCT design
is a strength, as it means that we can maximize the likeli-
hood that the differences observed between groups are
due to the intervention rather than potential confounders.
Blinding participants and researchers, and using a placebo
control would have increased this likelihood; however the
use of a pragmatic design, which mimics how the preload-
ing intervention would be carried out in practice, means
that resulting relative estimates of effectiveness will more
accurately represent what we would expect to see if the
intervention were carried out in a real-world setting. The
use of an intention-to-treat analysis also helps to ensure
this; not all participants will adhere to the treatment
recommended in their allocated study arm, however this
is what we would also expect to see in practice. Excluding
those participants who do not adhere to treatment from
the analysis may produce a biased estimate of effective-
ness. An intention-to-treat analysis also assumes that all
those participants lost to follow-up have returned to
smoking, which is standard practice in smoking cessation
trials; however we will report and assess attrition rates and
compare these between trial arms to investigate whether
there appears to be any factors associated with attrition.
We will also assess whether the assumption that those
with missing data are smokers affects study findings by
exploring alternative associations between missing data
and the odds of smoking [40]. Another strength of this
study is that it aims to recruit a large number of partic-
ipants (N = 1786), and so will have the power to detect
useful differences in effect between usual smoking ces-
sation support and the addition of nicotine preloading
treatment to this support, which no other previous trial has
been able to do. It will provide a significant contribution
to the existing pool of data in this area.
However, a potential barrier to recruiting such a large
sample is unexpected low response rates to recruitment
strategies. For this reason, although there is a core re-
cruitment strategy (sending letters from GP practices to
smokers and recruiting participants through a smoking
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outlined in the protocol that can be utilized where neces-
sary, such as using community and online advertising
mechanisms to recruit participants from the wider com-
munity. The use of several recruitment centers mean that
centers can try different strategies and share expertise.
The length of follow-up (12 months) is also a strength
of this study. Many smokers who make a quit attempt
will relapse; therefore long follow-up periods are needed
in order to gain a realistic impression of the impact that
a smoking cessation intervention will have, in terms of
long-term health and economic benefits. However, if a
nicotine preloading intervention has not shown an effect
at six months then there is no reason to believe that it
will have an effect at 12 months, and so a futility analysis
will be carried out using primary outcome data to estab-
lish whether a 12 month follow-up is necessary. This will
prevent the use of unnecessary resources and reduce
participant burden if there is no effect found on the
primary outcome at six months.
Finally, we seek to maximize the return on investment
by addressing several other questions in addition to the
primary one, which is the effectiveness of preloading.
However, our sample size calculation is based on the
primary outcome, as is standard practice in trials such
as this, and all analyses of additional outcomes will be
interpreted as secondary. By addressing the mechanism
of effect, we may be able to create tools that will allow
therapists to assess whether preloading is effective for
particular patients, as well as advancing the science of
understanding nicotine addiction. In addition, by collect-
ing data on participant weight and a blood sample for
genotyping (see Additional file 2), we can investigate
the impact of smoking cessation and relapse on weight
change, predictors of this weight change and potential
genetic predictors of smoking behaviors.
Trial status
Recruitment began in August 2012. At the time this manu-
script was submitted for publication the trial was still in the
recruitment phase, with 1311 participants recruited as of
the 12 June 2014. As response rates to letters from GP prac-
tices and the London smoker’s clinics advertisements have
been lower than expected, these core recruitment strategies
have been supplemented by the additional strategies listed
in the ‘Recruitment’ section above. This manuscript is based
on version 6.0 (30 July 2013) of the study protocol.
Additional files
Additional file 1: Pharmacovigilance. Further details on the
assessment of adverse events.
Additional file 2: Observational analyses. Details of secondary
investigations into genetics and weight gain.Abbreviations
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